Jason Oeh

2.3k total citations
21 papers, 956 citations indexed

About

Jason Oeh is a scholar working on Oncology, Molecular Biology and Geriatrics and Gerontology. According to data from OpenAlex, Jason Oeh has authored 21 papers receiving a total of 956 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Molecular Biology and 6 papers in Geriatrics and Gerontology. Recurrent topics in Jason Oeh's work include Sirtuins and Resveratrol in Medicine (6 papers), PARP inhibition in cancer therapy (6 papers) and Cancer therapeutics and mechanisms (4 papers). Jason Oeh is often cited by papers focused on Sirtuins and Resveratrol in Medicine (6 papers), PARP inhibition in cancer therapy (6 papers) and Cancer therapeutics and mechanisms (4 papers). Jason Oeh collaborates with scholars based in United States, France and Switzerland. Jason Oeh's co-authors include Deepak Sampath, Jenny Yao, Carlos Bais, Yinghui Guan, Ian Kasman, Xiumin Wu, Zhaoshi Jiang, Napoleone Ferrara, Guanglei Zhuang and Zora Modrušan and has published in prestigious journals such as The EMBO Journal, Blood and Cancer Research.

In The Last Decade

Jason Oeh

19 papers receiving 929 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jason Oeh United States	12	631	377	266	144	134	21	956
Antonia Cagnetta Italy	13	607 1.0×	106 0.3×	612 2.3×	151 1.0×	597 4.5×	38	1.2k
Kee Chuan Goh Singapore	16	596 0.9×	72 0.2×	389 1.5×	89 0.6×	119 0.9×	26	1.1k
Sheila Tze United States	8	1.3k 2.1×	280 0.7×	262 1.0×	64 0.4×	24 0.2×	8	1.6k
Weiqun Mao United States	20	546 0.9×	217 0.6×	310 1.2×	28 0.2×	22 0.2×	33	896
Wenwen Chien United States	20	822 1.3×	212 0.6×	250 0.9×	14 0.1×	60 0.4×	29	1.1k
Zi-Jie Long China	23	797 1.3×	239 0.6×	387 1.5×	12 0.1×	225 1.7×	29	1.4k
Pablo Baquero Spain	12	620 1.0×	246 0.7×	188 0.7×	12 0.1×	316 2.4×	17	959
Wei Wei Prior United States	8	644 1.0×	91 0.2×	199 0.7×	27 0.2×	32 0.2×	10	888
A.-E. Roske Germany	8	1.3k 2.1×	175 0.5×	445 1.7×	21 0.1×	54 0.4×	16	1.5k

Countries citing papers authored by Jason Oeh

Since Specialization

Citations

This map shows the geographic impact of Jason Oeh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jason Oeh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jason Oeh more than expected).

Fields of papers citing papers by Jason Oeh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jason Oeh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jason Oeh. The network helps show where Jason Oeh may publish in the future.

Co-authorship network of co-authors of Jason Oeh

This figure shows the co-authorship network connecting the top 25 collaborators of Jason Oeh. A scholar is included among the top collaborators of Jason Oeh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jason Oeh. Jason Oeh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Edgar, Kyle A., Rebecca Hong, Kyung Song, et al.. (2020). Abstract P3-11-23: GDC-0077 is a selective PI3K alpha inhibitor with robust efficacy in PIK3CA mutant hormone-positive breast cancer models. Cancer Research. 80(4_Supplement). P3–11. 2 indexed citations

Metcalfe, Ciara, Wei Zhou, Jane Guan, et al.. (2020). Abstract 3406: GDC-9545: A pure antiestrogen clinical candidate that immobilizes the estrogen receptor and profoundly alters chromatin accessibility in vivo. Cancer Research. 80(16_Supplement). 3406–3406. 4 indexed citations

Riegler, Johannes, Herman Gill, Annie Ogasawara, et al.. (2019). VCAM-1 Density and Tumor Perfusion Predict T-cell Infiltration and Treatment Response in Preclinical Models. Neoplasia. 21(10). 1036–1050. 24 indexed citations

Metcalfe, Ciara, Wei Zhou, Jane Guan, et al.. (2019). Abstract GS3-05: Prospective optimization of estrogen receptor degradation yields ER ligands with variable capacities for ER transcriptional suppression. Cancer Research. 79(4_Supplement). GS3–5. 1 indexed citations

Lasater, Elisabeth A., An D, Luciana Burton, et al.. (2018). Resistance of Natural Killer and T Cells to Venetoclax Allows for Combination Treatment with Cancer Immunotherapy Agents. Blood. 132(Supplement 1). 1118–1118. 3 indexed citations

Liederer, Bianca M., Jonathan Cheong, Kang-Jye Chou, et al.. (2018). Preclinical assessment of the ADME, efficacy and drug-drug interaction potential of a novel NAMPT inhibitor. Xenobiotica. 49(9). 1063–1077. 2 indexed citations

Shi, Yunzhou, Jason Oeh, A. Hitz, et al.. (2017). Monitoring and Targeting Anti-VEGF Induced Hypoxia within the Viable Tumor by 19 F–MRI and Multispectral Analysis. Neoplasia. 19(11). 950–959. 15 indexed citations

Punnoose, Elizabeth A., Joel Johansson, Franklin Peale, et al.. (2016). Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models. Molecular Cancer Therapeutics. 15(5). 1132–1144. 223 indexed citations

Zak, Mark, Po‐wai Yuen, Snahel Patel, et al.. (2016). Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors. Journal of Medicinal Chemistry. 59(18). 8345–8368. 26 indexed citations

10.

Ong, Christy C., Anneleen Daemen, Jason Oeh, et al.. (2016). Abstract 1803: Breast cancer cell lines with acquired resistance to selective ERα degraders (SERDs) are dependent on PI3K signaling. Cancer Research. 76(14_Supplement). 1803–1803. 1 indexed citations

11.

Poulin, Patrick, Yung‐Hsiang Chen, Xiao Ding, et al.. (2015). Prediction of Drug Distribution in Subcutaneous Xenografts of Human Tumor Cell Lines and Healthy Tissues in Mouse: Application of the Tissue Composition-Based Model to Antineoplastic Drugs. Journal of Pharmaceutical Sciences. 104(4). 1508–1521. 22 indexed citations

12.

Zabka, Tanja S., Jatinder Singh, Preeti Dhawan, et al.. (2014). Retinal Toxicity, in vivo and in vitro, Associated with Inhibition of Nicotinamide Phosphoribosyltransferase. Toxicological Sciences. 144(1). 163–172. 58 indexed citations

13.

Xiao, Yang, Kristi Elkins, Jenni Durieux, et al.. (2013). Dependence of Tumor Cell Lines and Patient-Derived Tumors on the NAD Salvage Pathway Renders Them Sensitive to NAMPT Inhibition with GNE-618. Neoplasia. 15(10). 1151–IN23. 64 indexed citations

14.

Dragovich, Peter S., Kenneth W. Bair, Yen‐Ching Ho, et al.. (2013). Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT). Bioorganic & Medicinal Chemistry Letters. 23(17). 4875–4885. 22 indexed citations

15.

Shi, Yunzhou, Jason Oeh, Jeffrey Eastham‐Anderson, et al.. (2013). Mapping In Vivo Tumor Oxygenation within Viable Tumor by 19F-MRI and Multispectral Analysis. Neoplasia. 15(11). 1241–IN1. 17 indexed citations

16.

O’Brien, Thomas, Jason Oeh, Yang Xiao, et al.. (2013). Supplementation of Nicotinic Acid with NAMPT Inhibitors Results in Loss of In Vivo Efficacy in NAPRT1-Deficient Tumor Models. Neoplasia. 15(12). 1314–IN3. 47 indexed citations

17.

Sampath, Deepak, Jason Oeh, Yang Xiao, et al.. (2013). Abstract B154: Co-administration of nicotinic acid with NAMPT small molecule inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.. Molecular Cancer Therapeutics. 12(11_Supplement). B154–B154. 1 indexed citations

18.

Zhuang, Guanglei, Xiumin Wu, Zhaoshi Jiang, et al.. (2012). Tumour‐secreted miR‐9 promotes endothelial cell migration and angiogenesis by activating the JAK‐STAT pathway. The EMBO Journal. 31(17). 3513–3523. 403 indexed citations

19.

Sampath, Deepak, Elizabeth A. Punnoose, Erwin R. Boghaert, et al.. (2012). Expression of Bcl-2 Pro-Survival Family Proteins Predicts Pharmacological Responses to ABT-199, a Novel and Selective Bcl-2 Antagonist, in Multiple Myeloma Models. Blood. 120(21). 5028–5028. 2 indexed citations

20.

Spencer, Jeffrey R., Martin Sendzik, Jason Oeh, et al.. (2006). Evaluation of antitumor properties of novel saframycin analogs in vitro and in vivo. Bioorganic & Medicinal Chemistry Letters. 16(18). 4884–4888. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact